# Kanker en hypertensie: gedeelde mechanismen, medicatie-interacties en klinisch beheer

*geplaatst 2026-10-08 · Hypertensie · Cancer medicine · doi 10.1002/cam4.72319 · https://hartvaat.nl/2026/10/01/kanker-en-hypertensie-gedeelde-mechanismen-medicatie-interacties-en-klinisch-beh/*

Deze narratieve review belicht de complexe wisselwerking tussen kanker en hypertensie, waarbij zowel gedeelde risicofactoren en biologische mechanismen (zoals chronische ontsteking en RAAS-activatie) als de invloed van oncologische therapieën op de bloeddruk centraal staan. De auteurs vatten de huidige aanbevelingen van de ESH en AHA samen voor het monitoren en behandelen van therapie-gerelateerde hypertensie, en benadrukken de noodzaak van een geïntegreerde cardio-oncologische benadering. Voor de klinische praktijk betekent dit dat cardiologen en internisten proactief de bloeddruk en cardiovasculaire risicofactoren moeten meewegen bij het opstellen van de oncologische behandelstrategie.

## English: Cancer and Hypertension: Shared Mechanisms, Treatment Interactions, and Clinical Management.

This narrative review examines the bidirectional relationship between cancer and hypertension, highlighting shared pathophysiological pathways such as chronic inflammation, RAAS activation, and metabolic dysregulation, alongside the impact of oncological treatments on blood pressure control. It synthesizes current European and American guidelines for managing cancer therapy-related hypertension, emphasizing routine cardiovascular risk assessment and the potential prognostic implications of treatment-induced BP changes. Clinicians should integrate proactive blood pressure monitoring and cardiometabolic risk management into oncology care pathways to optimize outcomes in this growing patient population.

## Abstract (original, from the publication)

Cancer and hypertension (HTN) frequently coexist, and their relationship is increasingly recognized as a clinically relevant intersection between oncology and cardiovascular medicine. However, the extent to which this association reflects shared risk factors, common biological mechanisms, or treatment-related effects remains incompletely understood. In this narrative review, we focus specifically on the cancer-HTN interface and summarize epidemiological evidence while considering the potential influence of age, obesity, metabolic syndrome, dietary patterns, and psychosocial factors. We further discuss overlapping mechanisms, including chronic inflammation, renin-angiotensin-aldosterone system activation, calcium signaling abnormalities, activation of the sympathetic nervous system, metabolic dysregulation, dysbiosis of the gut microbiota and genetic and epigenetic alterations. Particular attention is given to the bidirectional interactions between cancer therapies and HTN, as well as the heterogeneous evidence concerning potential associations between antihypertensive medications and cancer outcomes. We also summarize the clinical assessment and management of cancer therapy-related HTN, including Common Terminology Criteria for Adverse Events grading, blood pressure monitoring, cardiovascular risk assessment, and current recommendations from the European Society of Hypertension (ESH) and American Heart Association. Emerging issues, including immune checkpoint inhibitor-associated cardiovascular toxicity, the potential role of cardiac biomarkers such as troponin and natriuretic peptides, and the prognostic significance of treatment-induced HTN across different tumor types, are also discussed. Overall, the available evidence supports an important clinical interplay between cancer and HTN but does not establish a uniform causal relationship. Future prospective studies integrating tumor biology, cardiovascular risk factors, treatment exposure, and longitudinal blood pressure (BP) assessment are needed to clarify these interactions and improve individualized cardio-oncology care.

Auteurs: Peizhi Jia, Daxin Chen, Jingting Wang, Yupei Guo, Jinhong Liu, Jiumao Lin

---
Bron: Cancer medicine, https://doi.org/10.1002/cam4.72319. Bijgewerkt 2026-10-02T01:12:12Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.